<?xml version="1.0" encoding="UTF-8"?>
<p>The use of convalescent plasma for COVID-19 therapy was also considered an optimal alternative by the FDA, which, on 24 of March 2020, published the guidance for Investigational COVID-19 Convalescent Plasma that highlights the access pathways to this kind of treatment: (1) for compassionate use in severely or critically ill patients; (2) for clinical trials settings; and (3) to institutions that participate in a master treatment protocolâ€”a government led-initiative [
 <xref rid="B147-jcm-09-02084" ref-type="bibr">147</xref>,
 <xref rid="B149-jcm-09-02084" ref-type="bibr">149</xref>]. To gather more information about convalescent plasma efficacy/safety profile, multiple clinical trials (even phase 2) were set in motion and assessed the following directions: (i) treatment for mild forms of SARS-CoV-2 infection; (ii) treatment for moderately ill patients; (iii) as rescue intervention conducted in patients that are mechanically ventilated; (iv) safety and pharmacokinetics in high-risk pediatric patients; and (v) as post-exposure prophylaxis in patients that were in contact with COVID-19 positive patients, but do not present clinical symptomatology [
 <xref rid="B147-jcm-09-02084" ref-type="bibr">147</xref>].
</p>
